10-Q: Tempest Therapeutics Reports Positive Phase 1b/2 Data for Amezalpat in Liver Cancer, Advances Pipeline

Tempest Therapeutics announced positive updated results from its Phase 1b/2 trial of amezalpat in liver cancer, showing a 6-month improvement in median overall survival compared to the standard of care.

Summary

• Tempest Therapeutics is a clinical-stage biotechnology company focused on developing cancer treatments.
• The company's lead program, amezalpat, is poised to begin a pivotal study in first-line liver cancer.
• Updated data from the Phase 1b/2 trial of amezalpat combined with atezolizumab and bevacizumab showed a median overall survival of 21 months, compared to 15 months in the control arm.
• The hazard ratio for overall survival remained stable at 0.65, indicating a positive treatment effect.
• The confirmed objective response rate in the amezalpat arm was 30%, compared to 13.3% in the control arm.
• One patient in the amezalpat arm achieved a complete response, despite having a tumor profile not typically responsive to standard therapies.
• The company is also developing TPST-1495, a dual antagonist of the EP2 and EP4 receptors, and plans to advance it into a Phase 2 study for Familial Adenomatous Polyposis.
• Tempest Therapeutics had cash and cash equivalents of $31.1 million as of June 30, 2024.
• The company has incurred operating losses since inception and expects to incur additional losses in the future.
• They intend to raise additional capital through debt or equity issuances, potential mergers, or business development activities.
• The company believes its existing cash will be sufficient to fund operations for at least 12 months following the issuance of these financial statements.

Sentiment

Score: 7

Explanation: The document presents positive clinical data for amezalpat, which is a significant positive. However, the company's financial situation and need for additional funding temper the overall sentiment. The company is making progress but faces financial challenges.

Positives

• Amezalpat demonstrated a statistically significant improvement in overall survival in a Phase 1b/2 trial.
• The objective response rate for amezalpat was more than double that of the control arm.
• The company is actively exploring new indications for its product candidates, including kidney cancer and cholangiocarcinoma.
• The company has a diverse portfolio of targeted and immune-mediated product candidates.
• The company has a clear plan to advance amezalpat into a pivotal Phase 3 trial.
• The company is working with the Cancer Prevention Clinical Trials Network on a National Cancer Institute (NCI)-funded Phase 2 study for TPST-1495.

Negatives

• The company has incurred operating losses since inception and expects to incur additional losses in the future.
• The company's ability to continue as a going concern is dependent on its ability to secure additional financing.
• The company has not yet generated any revenue from product sales.
• The company's loan payable balance is $10.7 million as of June 30, 2024, with monthly principal payments of $733 thousand beginning on July 1, 2024.
• The company's research and development expenses increased by $1.4 million for the three months ended June 30, 2024, compared to the same period in 2023.

Risks

• The company's ability to continue as a going concern is dependent on its ability to secure additional financing.
• The company has a history of operating losses and may not achieve or sustain profitability.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company faces significant competition in the biotechnology industry.
• The company may not be able to protect its intellectual property rights.
• The company's stock price is volatile and may decline.
• The company's loan agreement with Oxford Finance contains financial covenants and restrictions that may limit operational flexibility.
• The company relies on third parties for manufacturing and clinical trial services, which could lead to delays or quality issues.
• The company may experience difficulties in managing its growth and attracting qualified personnel.
• The company's product candidates may cause undesirable side effects or be perceived as unsafe.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for at least the next several years as it continues clinical development and seeks regulatory approval for its product candidates. They believe their cash and cash equivalents will be sufficient to fund operations for at least the next 12 months. They plan to raise additional capital through debt or equity issuances, potential mergers, or business development activities.

Management Comments

• Management believes that its existing cash and cash equivalents will be sufficient to fund the Company's cash requirements for at least 12 months following the issuance of these financial statements.
• Management plans to secure sources of financing and ultimately attain profitable operations.

Industry Context

The company operates in the competitive biotechnology industry, specifically in the immuno-oncology space. The positive clinical data for amezalpat positions them well against competitors in the liver cancer treatment market. The company is also exploring new indications for its product candidates, which is a common strategy in the industry to maximize the potential of their assets.

Comparison to Industry Standards

• The reported median overall survival of 21 months for amezalpat in combination therapy is a significant improvement compared to the standard of care, which typically shows a median overall survival of around 15 months in first-line HCC.
• The objective response rate of 30% in the amezalpat arm is also higher than the typical response rates seen with atezolizumab and bevacizumab alone, which are usually in the range of 10-15%.
• Companies like Exelixis (Cabometyx) and Bayer (Sorafenib) have established treatments for HCC, but the data for amezalpat suggests a potential for a more effective treatment option.
• The development of TPST-1495 for Familial Adenomatous Polyposis is a novel approach, as there are currently no approved systemic therapies for this condition, setting Tempest apart from competitors in this specific area.
• The company's cash position of $31.1 million is relatively low for a clinical-stage biotech company, and they will need to raise additional capital to fund their operations and clinical trials, which is a common challenge for companies in this sector.

Stakeholder Impact

• Shareholders may benefit from the positive clinical data and potential for future growth, but face risks related to the company's financial situation and need for additional funding.
• Employees may benefit from the company's progress and potential for future success, but face risks related to the company's financial stability.
• Patients may benefit from the development of new and potentially more effective cancer treatments.
• Creditors face risks related to the company's financial situation and ability to repay its debts.

Next Steps

• Advance amezalpat into a pivotal study in first-line HCC patients, subject to obtaining feedback from the FDA.
• Explore TPST-1495 beyond original tumor types of interest, including completing the ongoing combination arm in patients with advanced endometrial cancer.
• Advance TPST-1495 with the Cancer Prevention Clinical Trials Network into a Phase 2 study in patients with FAP in the second half of 2024.

Key Dates

Keywords

Amezalpat, TPST-1495, Liver Cancer, Hepatocellular Carcinoma, Oncology, Biotechnology, Clinical Trial, PPAR antagonist, Prostaglandin antagonist, Drug Development, Phase 3 Trial, Familial Adenomatous Polyposis, ATM Program, Financial Results